Community Acquired Pneumonia (CAP): An Update

Summary Community-acquired pneumonia (CAP) remains a common and serious infectious disease worldwide. Recent investigations highlight the difficulties in making etiological diagnosis while emphasizing the importance of atypical pathogens in CAP. Prognostic tools such as the pneumonia severity index have been validated and widely endorsed as an aid in making site of care decisions in managing CAP patients. Empiric treatment guidelines for CAP have been developed and their use has been shown to simplify treatment regimens and improve outcome.

[1]  T. Marras,et al.  Applying a prediction rule to identify low-risk patients with community-acquired pneumonia. , 2000, Chest.

[2]  L. Mandell,et al.  Canadian guidelines for the initial management of community-acquired pneumonia: an evidence-based update by the Canadian Infectious Diseases Society and the Canadian Thoracic Society. The Canadian Community-Acquired Pneumonia Working Group. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[3]  Michael J Fine,et al.  Practice Guidelines for the Management of Community-Acquired Pneumonia in Adults , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[4]  T. Marrie,et al.  A controlled trial of a critical pathway for treatment of community-acquired pneumonia. CAPITAL Study Investigators. Community-Acquired Pneumonia Intervention Trial Assessing Levofloxacin. , 2000, JAMA.

[5]  A. Shibl,et al.  Penicillin-Resistant and -Intermediate Streptococcus pneumoniae in Saudi Arabia , 2000, Journal of chemotherapy.

[6]  D. Singer,et al.  Safely increasing the proportion of patients with community-acquired pneumonia treated as outpatients: an interventional trial. , 1998, Archives of internal medicine.

[7]  M. Kolczak,et al.  Incidence of Community-Acquired Pneumonia Requiring Hospitalization Results of a Population-Based Active Surveillance Study in Ohio , 1997 .

[8]  M. Fine,et al.  A prediction rule to identify low-risk patients with community-acquired pneumonia. , 1997, The New England journal of medicine.

[9]  M. Fine,et al.  The hospital discharge decision for patients with community-acquired pneumonia. Results from the Pneumonia Patient Outcomes Research Team cohort study. , 1997, Archives of internal medicine.

[10]  R. Peeling,et al.  Ambulatory patients with community-acquired pneumonia: the frequency of atypical agents and clinical course. , 1996, The American journal of medicine.

[11]  M. Leinonen,et al.  The etiology of community-acquired pneumonia among hospitalized patients during a Chlamydia pneumoniae epidemic in Finland. , 1995, The Journal of infectious diseases.

[12]  L. Jackson,et al.  Chlamydia pneumoniae (TWAR) , 1995, Clinical microbiology reviews.

[13]  T. Marrie,et al.  Serological investigation of pneumonia as it presents to the physician's office. , 1993, The Canadian journal of infectious diseases = Journal canadien des maladies infectieuses.

[14]  T. Marrie,et al.  Community-acquired pneumonia requiring hospitalization: 5-year prospective study. , 1989, Reviews of infectious diseases.

[15]  J. Washington,et al.  Trends in the antimicrobial susceptibility of bacterial respiratory tract pathogens--findings of the Alexander Project 1992-1996. , 1999, Journal of chemotherapy.

[16]  G. Campbell.  Overview of community-acquired pneumonia. Prognosis and clinical features. , 1994, The Medical clinics of North America.

[17]  L. Mandell,et al.  Antimicrobial treatment of community acquired pneumonia in adults: A conference report. , 1993, The Canadian journal of infectious diseases = Journal canadien des maladies infectieuses.